Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib
- 31 August 2020
- journal article
- research article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 61 (14), 3422-3431
- https://doi.org/10.1080/10428194.2020.1811270
Abstract
Bleeding is a common adverse event following ibrutinib monotherapy. However, it remains unclear how hemostasis is affected by venetoclax in combination with ibrutinib. Here we investigated hemostasis in patients with chronic lymphocytic leukemia (CLL) at baseline, during ibrutinib monotherapy, and during venetoclax and ibrutinib combination therapy or venetoclax monotherapy. Primary hemostasis, assessed by Multiplate using adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin receptor agonist peptide (TRAP-6), was impaired in all CLL patients at baseline, remained unchanged upon ibrutinib monotherapy, and improved significantly following venetoclax added to ibrutinib or as monotherapy. Secondary hemostasis assessed by thromboelastography (TEG) was normal and unchanged throughout treatment. The frequency of clinical bleeding events was the highest during ibrutinib monotherapy, in line with the demonstrated improved primary hemostasis upon addition of venetoclax, thus pointing toward a treatment option for CLL patients with increased bleeding risk.Keywords
Funding Information
- Novo Nordisk Foundation (NNF16OC0019302)
- Danish National Research Foundation (126)
This publication has 37 references indexed in Scilit:
- The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapiesSeminars in Cancer Biology, 2014
- Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function testscclm, 2014
- Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- Discrepant Fibrinolytic Response in Plasma and Whole Blood during Experimental Endotoxemia in Healthy VolunteersPLOS ONE, 2013
- Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263)Blood, 2013
- The B-cell receptor signaling pathway as a therapeutic target in CLLBlood, 2012
- The Influence of Low Platelet Count on Whole Blood Aggregometry Assessed by MultiplateClinical and Applied Thrombosis/hemostasis, 2011
- Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivoBlood, 2006
- Tec regulates platelet activation by GPVI in the absence of BtkBlood, 2003
- A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagenCurrent Biology, 1998